| Literature DB >> 28288135 |
D Thaper1,2, S Vahid1,2, K M Nip1,2, I Moskalev1, X Shan3, S Frees1, M E Roberts4, K Ketola1, K W Harder4, C Gregory-Evans3, J L Bishop1, A Zoubeidi1,2.
Abstract
The acquisition of an invasive phenotype by epithelial cells occurs through a loss of cellular adhesion and polarity, heralding a multistep process that leads to metastatic dissemination. Since its characterization in 1995, epithelial-mesenchymal transition (EMT) has been closely linked to the metastatic process. As a defining aspect of EMT, loss of cell adhesion through downregulation of E-cadherin is carried out by several transcriptional repressors; key among them the SNAI family of transcription factors. Here we identify for the first time that Lyn kinase functions as a key modulator of SNAI family protein localization and stability through control of the Vav-Rac1-PAK1 (Vav-Rac1-p21-activated kinase) pathway. Accordingly, targeting Lyn in vitro reduces EMT and in vivo reduces metastasis of primary tumors. We also demonstrate the clinical relevance of targeting Lyn as a key player controlling EMT; patient samples across many cancers revealed a strong negative correlation between Lyn and E-cadherin, and high Lyn expression in metastatic tumors as well as metastasis-prone primary tumors. This work reveals a novel pancancer mechanism of Lyn-dependent control of EMT and further underscores the role of this kinase in tumor progression.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28288135 DOI: 10.1038/onc.2017.5
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867